Significant Matters

Tsogo Sun Gaming / The Millenium Casino

26 May 2010|In Significant Matters

Nortons Inc. secured competition law approval for both Tsogo Sun Gaming and Millenium Casinos Limited (“Millenium”) in relation to the large merger between the two companies in terms of which Tsogo Sun Gaming acquired the entire issued share capital of Millenium from Johnnic Holdings Limited, a wholly owned subsidiary of Hosken Consolidated Investments Limited, a public company listed on the Johannesburg Stock Exchange. Millenium’s only asset was its indirect 40% shareholding in Tsogo Sun KZN.

Zhejiang Geely Holding Group / Ford Motor Co.

26 May 2010|In Significant Matters

Nortons Inc. represented Zhejiang Geely Holdings Group (“Geely”) in its US$1.8 billion acquisition of Volvo Cars from Ford Motors Co. in South Africa. Geely’s chairman described the deal as “a milestone” for both Geely and Volvo.

Tsogo Sun Holdings (Pty) Limited / Gold Reef Resorts Limited

26 May 2010|In Significant Matters

Nortons Inc. is representing Tsogo Sun Holdings (Pty) Limited (“Tsogo Holdings”) in securing competition law approval in relation to the large merger between Tsogo Holdings and Gold Reef Resorts Limited (“Gold Reef”) which will see the parties merging their respective gaming and hotel businesses. The proposed merger will be effected through an acquisition by Gold Reef of the Tsogo shares held by Tsogo Investment Holdings Company (Pty) Limited (“TIH”) and SABSA Holdings (Pty) Limited (“SABSA”) in exchange for the issue of new Gold Reef shares to form a merged company, which will be listed on the Johannesburg Stock Exchange. Tsogo Holdings looks set to become the world’s seventh-largest listed hotel and casino group once the merger with Gold Reef Resorts takes place.

Aspen / certain OTC products of GSK

26 May 2010|In Significant Matters

Nortons Inc. is representing Aspen Pharmaceuticals (“Aspen”) and GlaxoSmithKline in relation to Aspen acquiring a portfolio of products from GlaxoSmithKline, in so far as they are sold to the “rest of the world”, excluding North America and Europe. The portfolio of products include Solpadeine, Phillips MOM, Zantac, Nytol, Cartia, Valad, Beconase, Dequadin, Borstol, Cofal, Hedex, Kwell, Cafenol, Valoid, Aspirin concept, Cortal, Brooklax, Cofta, Lipeze, Alphosyl, Quellada, Paramed, Specific Pain Remedy, Calsuba, Glucolin, Cytexin, Decavit Plus and Ashton & Parsons (“the Prism products”). Upon completion of the proposed transaction, Aspen will acquire sole control over the Prism products. Nortons Inc. is assisting the merging parties with notifying the proposed transaction in a number of African jurisdictions, including South Africa, Namibia, Swaziland, Kenya and Tanzania. The transaction has also been notified in Brazil.

NEWER NEWER 1 2 4 5